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Sir,
We thank Dr C Alliot for his comments and critique in the
editorial accompanying our article (Ohwada et al, 2004). Regarding
the choice of the control arm, we agree that the standard adjuvant
treatment for stage III colon cancer since 1990 has been 5-
fluorouracil plus leucovorin (5-FU/LV) (NIH, 1990; IMPACT, 1995;
Wolmark et al, 1999). Now, FOLFOX has become a standard
regimen for stage II or III colorectal cancer (Andre et al, 2004).
Nevertheless, the Ministry of Health and Welfare of Japan did not
approve LV for colorectal cancer until June 16, 1999. This study
was conducted between October 1994 and March 1997, 2 years
before official permission. Therefore, LV was unavailable as a
randomised control. As you indicated, there is currently no
evidence that UFT is superior to the standard regimen, even when
modulated by LV. In a large phase III trial that compared UFT/LV
with 5-FU/LV for untreated metastatic colorectal cancer, UFT/LV
was found to be a safer, more convenient oral alternative to a
standard bolus IV 5-FU/LV regimen, while producing equivalent
survival; however, it was associated with an inferior time to disease
progression and 22% increase in the risk of disease progression
(Douillard et al, 2002). Recently, the efficacy of UFT has been
determined. In randomised, controlled trials, adjuvant chemother-
apy with UFT alone improved the survival of patients with
completely resected pathological stage III rectal cancer (Akatsu
et al, 2004) and stage I adenocarcinoma of the lung (Kato et al,
2004), compared with surgery alone.
Dr Alliot was concerned with the high proportion of patients
with rectal cancer in the control arm, the impact of the quality of
surgery, and the fact that no preoperative radiotherapy was
administered. The 5-year disease-free survival for rectal cancer was
69.4% (95% CI: 56.5–82.3%) with PSK and 52.9% (95% CI: 36.2–
69.7%) in the controls (P¼0.133). The difference was not
significant, but the high proportion of patients with rectal cancer
in the control arm may have pushed the survival for all the patients
downward. Therefore, we reanalysed the 5-year disease-free
survival adjusted for histologic type and tumour location and
found that the survival remained significantly better for the PSK
group (stratified logrank; P¼0.031). The result suggests that the
high proportion of patients with rectal cancer did not affect the
survival significantly.
As Dr Alliot indicated, the quality of surgery is an important
point when conducting any randomised, controlled trial in a
surgical field. The recognition that tumour cell involvement in the
circumferential margin is important in local recurrence has led to
the general use of total mesorectal excision (MacFarlane et al,
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enveloped and resected using a precise, sharp dissection. There-
fore, suitably qualified chief surgeons were trained in the Second
Department of Surgery, Gunma University Hospital, in order to
standardise surgical quality. We applied total mesorectal resection
for Rb or Rab tumours, and tumour-specific mesorectal resection
for Ra tumours (at least 4cm of the anal mesorectum was
dissected). Lateral node dissection was performed, while groin
dissection was not added. In our study of rectal cancer, the rate of
local recurrence was 4.8% in all patients, 2.9% in the control, and
6.1% in the PSK group. The low rate of local recurrence in our
study with no preoperative radiation therapy (4.8% at 5 years) is
similar to the excellent results achieved using preoperative
radiation therapy and standard resection (Kapiteijn et al, 2001).
Oncologists agree that an early start for chemotherapy is
rationally correct, because surgery provokes the circulation of
neoplastic cells (Yamaguchi et al, 2000), angiogenesis, and,
potentially, the development of micrometastasis, as Dr Alliot
indicated. In his editorial, Dr Alliot does not focus on the superior
results in the PSK arm, but emphasises the poor results in the
control arm. The benefits of an early start for chemotherapy are
supported by the significantly superior disease-free survival in the
PSK arm. The survival of UFT/MMC in pathologic stage III
patients was poor and was similar to that of untreated controls in
standard regimens (Francini et al, 1994; IMPACT, 1995). This may
be explained by the difference in the dose intensity of UFT. The
UFT doses used in positive randomised trials include
600mgbodyday
 1 (Malik et al, 1990), 300 or 350mgm
 2day
 1
with LV (Douillard et al, 2002), 400mgm
 2 for 5 of 7 days (Akatsu
et al, 2004), and 250mgm
 2day
 1 (Kato et al, 2004), which are all
higher than the 300mgbody
 1 used in our study, despite the lack
of LV modulation. The development of more effective agents or
regimens should prove that an early start with chemotherapy
benefits disease-free survival.
Invoking recently published data from randomised, controlled
trials, the survival with PSK/UFT treatment is comparable or
superior to standard 5-FU/LV regimens. The 5-year disease-free
and overall survival rates were 73.0 and 81.8% for the PSK group,
respectively, while the best 5-year disease-free and overall survival
rates were 65 and 76%, respectively, in NASBP C-04 (Wolmark
et al, 1999), and 63 and 70%, respectively, in Intergroup-0089-46-
51 (O’Connell et al, 1998). When limited to stage III patients, the 4-
year disease-free and overall survival rates were 69.1 and 78.2% in
the PSK group vs 65.3–72.8% for the latter (Porschen et al, 2001).
Further, in the MOSAIC trial (Andre et al, 2004), the 3-year
disease-free survival rates of stage II or III patients were 72.9% for
5FM/LV and 78.2% for FOLFOX, while we achieved 77.8% for PSK/
UFT. When limited to stage III, the 3-year disease-free survival
rates were 65.3% for 5FM/LV and 72.2% for FOLFOX, while we
obtained 70.9% for PSK/UFT.
I agree that disease-free survival is more meaningful than overall
survival, at least in the case of adjuvant chemotherapy for
colorectal cancer (Elfenbein, 2003; Andre et al, 2004); second-line
therapies for recurrence, including chemotherapy and salvage
surgery, can prolong the survival of colorectal cancer patients (de
Gramont et al, 2000; Saltz et al, 2000; Choti et al, 2002).
There is no consensus on the optimal duration for adjuvant
chemotherapy after colorectal cancer. Currently, a standard
adjuvant treatment for stage III colon cancer, is 5-FU/LV for 6–
12 months (Francini et al, 1994; O’Connell et al, 1998; IMPACTB2,
1999; Wolmark et al, 1999; QUASAR, 2000; Andre et al, 2004).
Recurrences generally occur within 2 years after surgery. Indeed,
in our study, 71% of cancers recurred during the first 2 years after
surgery, and 85% recurred within 21
2 years. The mean time to
recurrence was 1.971.4 years in the PSK group and 1.671.1 years
in the control group (P¼0.585). Porschen et al (2001) reported
that the median time to relapse was 15 months with 5FU/LV
treatment and 12 months with 5FU/levamisole treatment. Fluor-
ouracil is a time-dependent agent, and a daily regimen of UFT is an
effective way to maintain the blood fluorouracil level. Therefore,
the daily, long-term administration of UFT may be beneficial. In
addition, oral use of adjuvant chemotherapy with PSK and UFT is
less toxic and less complex, as it avoids frequent treatment-related
visits and thereby allows patients to receive long-term treatment.
PSK has a wide range of biological activity, remarkable immune-
enhancing activity, and a broad antineoplastic scope (Wasser,
2002). Therefore, therapy with PSK differs from therapy with
cytokines, such as interferon (IFN) and interleukin (IL)-2. PSK
activates NK cells independent of IFN and the IL-2/IL-2 receptor
system, and activates lymphokine-activated killer (LAK) cells
(Ebina and Murata, 1992; Algarra et al, 1997; Harada et al, 1997;
Pedrinaci et al, 1999; Garcia-Lora et al, 2001; Garcia-Lora et al,
2003). PSK also functions as a specific biochemical modulator of
antitumour agents, such as mitomycin C, 5-fluorouracil, cyclopho-
sphamide, bleomycin, CPT-11, cisplatin, and docetaxel (Zhang
et al, 2003). PSK upregulates the IL-1, IL-6, and IL-8 genes in
peripheral mononuclear cells (Hirose et al, 1990), as well as the
genes for TNF and macrophage chemotactic factors in tumour cells
(Ebina and Murata, 1992), and induces apoptosis (Yefenof et al,
1995; Zhang et al, 2003). In addition, PSK induces differentiation-
related genes and produces leukemic cell differentiation in vitro
(Yefenof et al, 1995). Furthermore, PSK suppresses tumour cell
invasiveness via the downregulation of several invasion-related
factors, which include TGF-b1, urokinase plasminogen activator,
and the matrix metalloproteinase (MMP)-2 and -9 (Zhang et al,
2000). These activities of PSK are varied and differ from those of
levamisole. Although the efficacy of levamisole in a randomised,
controlled trial was questionable (QUASAR, 2000), the results for
levamisole did not represent those for PSK.
Finally, I thank Dr C Alliot for his comments again. This study
shows that PSK is a good candidate for convenient therapy with
less toxicity, better compliance, and comparable survival to
FOLFOX or 5FU/LV regimens, although our results are not
definitive.
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